









市场行情
/
股票
/
nasdaq-nams
/

NewAmsterdam Pharma Company NV

NAMS

35.110USD

+1.210+3.57%

收盘 12/19, 16:00（美东）报价延迟15分钟

3.97B总市值

亏损市盈率 TTM



NewAmsterdam Pharma Company NV

35.110

+1.210+3.57%

概览公司财务分析

概览

公司

财务

分析

关于 NewAmsterdam Pharma Company NV 公司

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

NewAmsterdam Pharma Company NV简介



公司代码NAMS

公司名称NewAmsterdam Pharma Company NV

上市日期Nov 23, 2022

CEODavidson (Michael Harvey)

员工数量68

证券类型Ordinary Share

年结日Nov 23

公司地址Gooimeer 2-35

城市NAARDEN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Netherlands

邮编1411 DC

电话31352062971

网址https://ir.newamsterdampharma.com/

公司代码NAMS

上市日期Nov 23, 2022

CEODavidson (Michael Harvey)

NewAmsterdam Pharma Company NV公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Mark C. Mckenna

Independent Director

6.96K

Mr. Wouter Joustra

Independent Director

Dr. Michael Harvey Davidson, M.D.

Chief Executive Officer, Executive Director

Mr. William H. (Will) Lewis, J.D.

Independent Chairman of the Board

-100.00%

Ms. Louise Kooij

Interim Chief Financial Officer

Ms. Adele M. Gulfo

Independent Director

Dr. Louis Lange, M.D., Ph.D.

Independent Director

Dr. Marc Ditmarsch, M.D.

Chief Development Officer

Dr. James N. Topper, M.D., Ph.D.

Independent Director

Mr. Douglas Kling

Chief Operating Officer

名称

名称/职务

职务

持股

持股变动

Mr. Mark C. Mckenna

Independent Director

6.96K

Mr. Wouter Joustra

Independent Director

Dr. Michael Harvey Davidson, M.D.

Chief Executive Officer, Executive Director

Mr. William H. (Will) Lewis, J.D.

Independent Chairman of the Board

-100.00%

Ms. Louise Kooij

Interim Chief Financial Officer

Ms. Adele M. Gulfo

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月19日周三

持股股东

股东类型

持股股东

占比

Frazier Life Sciences Management, L.P.

14.73%

RA Capital Management, LP

8.94%

Capital World Investors

8.66%

Forbion Capital Partners

8.12%

Viking Global Investors LP

5.71%

其他

53.83%

持股股东

占比

Frazier Life Sciences Management, L.P.

14.73%

RA Capital Management, LP

8.94%

Capital World Investors

8.66%

Forbion Capital Partners

8.12%

Viking Global Investors LP

5.71%

其他

53.83%

股东类型

持股股东

占比

Investment Advisor

29.00%

Investment Advisor/Hedge Fund

24.03%

Venture Capital

20.18%

Private Equity

14.73%

Hedge Fund

13.06%

Research Firm

2.38%

Family Office

1.70%

Sovereign Wealth Fund

0.44%

Individual Investor

0.43%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

283

121.74M

107.54%

+4.12M

2025Q2

263

127.89M

114.87%

+4.67M

2025Q1

255

126.71M

112.87%

+7.17M

2024Q4

216

108.34M

98.72%

+13.96M

2024Q3

194

82.73M

88.90%

-12.05M

2024Q2

184

81.92M

90.19%

-12.22M

2024Q1

155

81.92M

90.50%

-4.21M

2023Q4

117

72.34M

86.57%

-9.73M

2023Q3

116

71.44M

85.50%

-13.42M

2023Q2

109

71.10M

86.48%

+7.09M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Frazier Life Sciences Management, L.P.

16.63M

14.76%

+18.71K

+0.11%

Aug 18, 2025

RA Capital Management, LP

10.14M

Jun 30, 2025

Capital World Investors

8.39M

7.45%

+1.59M

+23.37%

Jun 30, 2025

Forbion Capital Partners

9.32M

8.27%

-1.26M

-11.93%

Sep 26, 2025

Viking Global Investors LP

6.98M

6.2%

Jun 30, 2025

Bain Capital Life Sciences Investors, LLC

10.72M

9.52%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.83M

1.62%

+863.17K

+89.58%

Jun 30, 2025

Deerfield Management Company, L.P.

5.12M

4.54%

+1.01M

+24.66%

Jun 30, 2025

Jennison Associates LLC

2.95M

2.62%

-1.02M

-25.79%

Jun 30, 2025

Wellington Management Company, LLP

3.32M

2.95%

-218.98K

-6.18%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Global X Guru Index ETF

1.82%

ALPS Medical Breakthroughs ETF

1.81%

Virtus LifeSci Biotech Clinical Trials ETF

1.22%

First Trust Small Cap Growth AlphaDEX Fund

1.05%

First Trust NASDAQ Pharmaceuticals ETF

0.83%

Capital Group US Small and Mid Cap ETF

0.68%

ProShares Ultra Nasdaq Biotechnology

0.57%

Invesco Dorsey Wright SmallCap Momentum ETF

0.55%

First Trust Small Cap Core Alphadex Fund

0.43%

Invesco Nasdaq Biotechnology ETF

0.42%

Global X Guru Index ETF

占比1.82%

ALPS Medical Breakthroughs ETF

占比1.81%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.22%

First Trust Small Cap Growth AlphaDEX Fund

占比1.05%

First Trust NASDAQ Pharmaceuticals ETF

占比0.83%

Capital Group US Small and Mid Cap ETF

占比0.68%

ProShares Ultra Nasdaq Biotechnology

占比0.57%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.55%

First Trust Small Cap Core Alphadex Fund

占比0.43%

Invesco Nasdaq Biotechnology ETF

占比0.42%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

NewAmsterdam Pharma Company NV的前五大股东是谁？



NewAmsterdam Pharma Company NV 的前五大股东如下：
Frazier Life Sciences Management, L.P.持有股份：16.63M，占总股份比例：14.76%。
RA Capital Management, LP持有股份：10.14M，占总股份比例：9.00%。
Capital World Investors持有股份：8.39M，占总股份比例：7.45%。
Forbion Capital Partners持有股份：9.32M，占总股份比例：8.27%。
Viking Global Investors LP持有股份：6.98M，占总股份比例：6.20%。